| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Crenigacestat | JSMD-194; LY-3039478; BMS-986405 | Phase 2 Clinical | Eli Lilly And Company | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasm Metastasis; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Breast Neoplasms; Leiomyosarcoma; Sarcoma; Cholangiocarcinoma; Multiple Myeloma; Carcinoma, Adenoid Cystic; Colonic Neoplasms; Triple Negative Breast Neoplasms; Solid tumours; Lymphoma, B-Cell | Details |